1H-咪唑并[4,5-b]吡啶,2-(2-噻嗯基)- | 1204-64-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 1H-咪唑并[4,5-b]吡啶,2-(2-噻嗯基)-
• 英文名称: 2-(thiophen-2-yl)-3H-imidazo[4,5-b]pyridine
• 英文别名: 2-thiophen-2-yl-1H-imidazo[4,5-b]pyridine
• CAS: 1204-64-4
• 化学式: C₁₀H₇N₃S
• 分子量: 201.252
• InChiKey: MFUFVMDJHGXUND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-噻吩甲醛 在 氯化亚砜 作用下， 以 二氯甲烷 、 氯苯 为溶剂， 反应 5.0h， 生成 1H-咪唑并[4,5-b]吡啶,2-(2-噻嗯基)-
  参考文献：
  名称：

  Eynde, Jean-Jacques Vanden; Mayence, Annie; Maquestiau, Andre, Bulletin des Societes Chimiques Belges, 1993, vol. 102, # 5, p. 357 - 364

  摘要：

  DOI：

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• Viral treatment
  申请人：The Procter & Gamble Company

  公开号：US20030232851A1

  公开（公告）日：2003-12-18

  A pharmaceutical composition that inhibits or slows the growth of viruses is disclosed. This same composition is can be used to treat viral infections, particularly HIV and hepatitis as well as fungal infections of the genus cryptococcus neoformans or curvularai lunata. The composition comprises from about 10 mg to about 6000 mg of a 2-thienyl-imidazolo [4,5]pyridine of the formula: 1 wherein n is from 1 to 4, R is selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, hydroxy, sulfhydryl, alkoxy having the formula —O(CH 2 ) y CH 3 wherein y is from 1 to 6, the prodrugs thereof, and the pharmaceutically acceptable salts thereof. The preferred anti-viral compound is 2 and its hydrochloride salt. Mixtures of the 2-thienyl imidazolo [4,5] pyridines can also be used to treat viral infections.

  本发明揭示了一种能抑制或减缓病毒生长的药物组合物。该组合物可用于治疗病毒感染，特别是艾滋病毒和肝炎以及新生隐球菌属或曲霉菌属的真菌感染。该组合物包括从约10毫克到约6000毫克的2-噻吩基咪唑并[4,5]吡啶的化合物，其化学式为：1其中n为1至4，R选择自羟基、氢、1至7个碳原子的烷基、氯、溴或氟、氧氯、磺酰基、—O(CH2)yCH3（其中y为1至6）的烷氧基、其前药和药学上可接受的盐。首选的抗病毒化合物是2及其盐酸盐。2-噻吩基咪唑并[4,5]吡啶的混合物也可用于治疗病毒感染。
• GABA-B RECEPTOR MODULATORS
  申请人：Bauer Udo

  公开号：US20090149474A1

  公开（公告）日：2009-06-11

  The present invention relates to novel imidazole derivatives having a positive allosteric GABA B receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABA B agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R 1 , R 2 , R 3 and R 4 are as defined in the description. For example, R 1 may be phenyl, R 2 may be dimethylamino pyrrolidin-1-yl, R 3 may be alkoxy and R 4 may be alkyl, ai arylalkyl, aryloxyalkyl, aryloxy or heterocyclylalkyl.

  本发明涉及具有正向变构GABAB受体（GBR）调节剂作用的新型咪唑衍生物，以及制备这些化合物的方法和它们的用途，可选择与GABAB激动剂联合使用，用于抑制短暂性下食管括约肌松弛，治疗胃食管反流病，以及治疗功能性胃肠疾病和肠易激综合征（IBS）。这些化合物由通式（I）表示，其中R1、R2、R3和R4在描述中定义。例如，R1可以是苯基，R2可以是二甲基氨基吡咯烷-1-基，R3可以是烷氧基，R4可以是烷基、芳基烷基、芳氧基烷基、芳氧基或杂环烷基。
• Direct synthesis of benzimidazoles by Pd(II) N^N^S-pincer type complexes via acceptorless dehydrogenative coupling of alcohols with diamines
  作者：Pennamuthiriyan Anandaraj、Rengan Ramesh、Jan Grzegorz Malecki

  DOI：10.1016/j.jorganchem.2022.122577

  日期：2023.2

  geometry of the synthesized complexes 1 and 2 was confirmed by single-crystal X-ray diffraction study. A wide range of benzimidazole derivatives (32 examples) up to 94% isolated yield has been derived via acceptorless dehydrogenative coupling of primary alcohols with derivatives of o-phenylenediamines. The present protocol operates smoothly with only 1 mol% catalyst loading. Furthermore, the mechanistic

  报道了一种通过钯催化剂对伯醇进行无受体脱氢偶联来构建取代苯并咪唑的可持续合成方法。合成了三种新的非经典对称 Pd(II) N^N^S 钳状配合物 ( 1–3 )，并通过光谱（FT-IR、UV-vis、NMR 和 ESI-MS）和分析技术对其进行了表征。此外，通过单晶 X 射线衍射研究证实了合成配合物1和2的扭曲方形平面几何形状。通过伯醇与o的衍生物的无受体脱氢偶联，衍生出范围广泛的苯并咪唑衍生物（32 个实例），分离产率高达 94%- 苯二胺。本协议运行平稳，催化剂负载量仅为 1 mol%。此外，在对照实验的帮助下进行的机理研究表明，反应是通过原位生成醛中间体进行的，并生成氢气和水作为唯一的副产物。
• Microwave-assisted one step high-throughput synthesis of benzimidazoles
  作者：Shou-Yuan Lin、Yuko Isome、Ethan Stewart、Ji-Feng Liu、Daniel Yohannes、Libing Yu

  DOI：10.1016/j.tetlet.2006.02.127

  日期：2006.4

  One-pot synthesis of benzimidazoles from diamines and carboxylic acids was developed under microwave irradiation condition, which provided a practical and efficient method for high-throughput synthesis of this important class of heterocyclic compounds. (c) 2006 Elsevier Ltd. All rights reserved.